Literature DB >> 7524561

Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor.

J M Sullivan1, S F Traynelis, H S Chen, W Escobar, S F Heinemann, S A Lipton.   

Abstract

Modulation of NMDA-mediated responses by oxidizing and reducing reagents has been described in a variety of neuronal preparations. Here, we report that NMDA-gated currents of oocytes expressing heteromeric NMDA receptors are also modulated by sulfhydryl redox reagents. Each cysteine residue in the NMDAR1 (NR1) subunit and each conserved NMDAR2 (NR2) cysteine residue in a prototypical subunit (NR2B) was tested for its role in redox modulation. We have identified 2 cysteines in the NR1 subunit that are required for redox modulation of NMDA-gated currents in oocytes expressing NR1-NR2B, NR1-NR2C, or NR1-NR2D receptors. Mutation of these same 2 cysteines also eliminated potentiation by spermine and shifted the IC50 for H+ inhibition and the EC50 for NMDA. Redox modulation of heteromeric NR1-NR2A receptors appeared to be different from that of the other heteromeric receptors, indicating the presence of one or more unique redox modulatory sites on NR1-NR2A receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524561     DOI: 10.1016/0896-6273(94)90258-5

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  66 in total

1.  High-affinity zinc inhibition of NMDA NR1-NR2A receptors.

Authors:  P Paoletti; P Ascher; J Neyton
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  Modulation of neuronal and recombinant GABAA receptors by redox reagents.

Authors:  A Amato; C N Connolly; S J Moss; T G Smart
Journal:  J Physiol       Date:  1999-05-15       Impact factor: 5.182

3.  Redox modulation of basal and beta-adrenergically stimulated cardiac L-type Ca(2+) channel activity by phenylarsine oxide.

Authors:  Carl Sims; Robert D Harvey
Journal:  Br J Pharmacol       Date:  2004-06-01       Impact factor: 8.739

4.  GluN1-specific redox effects on the kinetic mechanism of NMDA receptor activation.

Authors:  Iehab Talukder; Rashek Kazi; Lonnie P Wollmuth
Journal:  Biophys J       Date:  2011-11-15       Impact factor: 4.033

Review 5.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

6.  Novel role for the NMDA receptor redox modulatory site in the pathophysiology of seizures.

Authors:  R M Sanchez; C Wang; G Gardner; L Orlando; D L Tauck; P A Rosenberg; E Aizenman; F E Jensen
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

7.  Reducing agents sensitize C-type nociceptors by relieving high-affinity zinc inhibition of T-type calcium channels.

Authors:  Michael T Nelson; Jiwan Woo; Ho-Won Kang; Iuliia Vitko; Paula Q Barrett; Edward Perez-Reyes; Jung-Ha Lee; Hee-Sup Shin; Slobodan M Todorovic
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

8.  Modulation of the dimer interface at ionotropic glutamate-like receptor delta2 by D-serine and extracellular calcium.

Authors:  Kasper B Hansen; Peter Naur; Natalie L Kurtkaya; Anders S Kristensen; Michael Gajhede; Jette S Kastrup; Stephen F Traynelis
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

9.  Neuronal growth on L- and D-cysteine self-assembled monolayers reveals neuronal chiral sensitivity.

Authors:  Koby Baranes; Hagay Moshe; Noa Alon; Shmulik Schwartz; Orit Shefi
Journal:  ACS Chem Neurosci       Date:  2014-03-05       Impact factor: 4.418

10.  The Inhibition of TREK2 Channel by an Oxidizing Agent, 5,5'-dithio-bis (2-nitrobenzoic acid), via Interaction with the C-terminus Distal to the 353rd Amino Acid.

Authors:  Kyoung Sun Park; Hyoweon Bang; Eun-Young Shin; Chan Hyung Kim; Yangmi Kim
Journal:  Korean J Physiol Pharmacol       Date:  2008-08-31       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.